AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
'Vasomotor symptoms of menopause affect millions of women, with significant impacts on their well-being, and their personal and professional lives,' said Natalya Nazarenko, MD, Executive Medical Director at AbCellera. 'We are excited to advance ABCL635 into a Phase 1 trial and explore it as a potential non-hormonal, long-acting treatment option to address these highly disruptive symptoms.'
The Phase 1 study is anticipated to begin in Q3 of 2025 and will evaluate ABCL635's safety, pharmacokinetics, and pharmacodynamics in healthy participants and postmenopausal women with moderate-to-severe VMS.
About ABCL635
ABCL635 is a potential first-in-class antibody medicine for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. ABCL635 specifically targets NK3R, a clinically validated G-coupled protein receptor (GPCR) expressed on kisspetin, neurokinin, and dynorphin (KNDy) neurons in the infundibular nucleus of the hypothalamus. ABCL635 is the first program from AbCellera's GPCR and ion channel platform to advance into the pipeline. A Phase 1 clinical trial is anticipated to begin in Q3 of 2025.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under 'Risk Factors,' 'Management's Discussion and Analysis of Financial Condition and Results of Operations,' and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
1 Lé AM, Torres T. Pharmaceutics. 2022 Dec 8;14(12):2753.
2 Guttman-Yassky E, et al. 2024 Sep 18;191(4):488-496.
3 Weidinger S, et al. J Allergy Clin Immunol. 2024 Nov 8:S0091-6749(24)01175-8.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Develop Health Raises $14.3M to Automate Prior Authorization and Medication Access Using GenAI
SAN FRANCISCO--(BUSINESS WIRE)-- Develop Health, an EHR-integrated benefits‑verification and prior‑authorization platform, today announced a $14.3 million Series A led by Wing Venture Capital, with participation from Afore Capital, J Ventures, and South Park Commons. The round brings the company's total funding to $17.6 million. Built with over a dozen purpose-built large language model pipelines, Develop Health is the first medication access platform fully architected around GenAI. Its EHR-integrated platform plugs into virtual care workflows to verify insurance coverage in real time, generate and submit the correct prior authorization package, follow up and track status continuously, and return structured data back into the provider's system, all without manual effort from care teams. Founded by Mel van Londen and Benjamin Easton, Develop Health is tackling a growing bottleneck in healthcare: the administrative complexity that delays access to necessary medications. Before Develop Health, the founders held roles at provider-facing healthcare startups Canvas Medical and Rupa Health, where they saw how poor communication and data fidelity between providers and payers led to delayed treatment, lost revenue, and worse outcomes for patients. 'We believe providers should be able to make care decisions with full visibility into a patient's plan, because a prescription that isn't affordable or accessible is no prescription at all,' said Mel van Londen, co-founder and CEO of Develop Health. 'We're building healthcare's agentic clearinghouse, starting with medication access and designing infrastructure that meets both payers and providers where they are.' The new funding will fuel Develop Health's expansion beyond its core work helping digital health companies navigate the pharmacy benefit space—spanning GLP-1s and treatments across addiction, neurology, dermatology, and psychiatry—into the medical benefit market. The company will also deepen its integrations with both EHRs and PBMs, streamlining and scaling the link between prescribing and coverage, and extend its reach into traditional providers outside of digital health. 'Develop Health is solving one of the most frustrating pain points in healthcare – getting patients the medications they need without weeks of paperwork and endless back-and-forth,' said Sara Choi, Partner at Wing Venture Capital. 'They've built a system that puts GenAI to work in one of the industry's most critical, overlooked workflows. Develop Health is positioned to become essential infrastructure for any provider dealing with medication access complexity. ' Today, Develop Health helps providers reduce churn, set clearer patient expectations, and streamline access to care. The platform reduces form completion time by over 80% and increases approval rates, improving both provider efficiency and patient experience. In just three months, the company has grown significantly and is on track to helping over 1 million patients access their medications by the end of this year. That traction has been driven by Develop Health's exceptional team of engineers, including Jack Collins, Juan de Urtubey, and Zygimantas Koncius, whose technical excellence has made the platform possible. About Develop Health Develop Health's mission is to empower providers by eliminating the friction of prior authorization and improving visibility into plan benefits—freeing up capacity to deliver truly high-quality patient care. At its core, Develop Health is healthcare's agentic clearinghouse, beginning with medication access. Today, the platform supports hundreds of thousands of patients each month in getting the treatments they need—while reducing administrative work related to medication access by 83%. Learn more at
Business Wire
2 hours ago
- Business Wire
Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced a Nature publication describing robust pre-clinical tumor suppression and novel mechanistic insights from inhibiting the binding of certain protein substrates (that bind via RxL motifs) to cyclins A and B in E2F-high tumor cells. Circle Pharma's oral cyclin A/B RxL inhibitor, CID-078, is a first-in-class, orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors. Cyclins (including cyclins A and B) are a family of proteins that function as master regulators of the cell cycle by binding to and activating their catalytic partners, the cyclin-dependent kinases (CDKs). Cancers driven by high E2F activity, such as small cell lung cancer (SCLC) and other tumors with RB1 alterations, have an overactive cell cycle that leads to uncontrolled tumor cell proliferation. In preclinical models, cyclin A/B RxL inhibitors: Blocked the cyclin A-E2F interaction, triggering aberrant sustained E2F activity, DNA damage, and replication stress. Subsequently disrupted the cyclin B-Myt1 interaction, removing a critical safety brake and forcing damaged tumor cells through division, causing tumor cell death. Produced robust anti-tumor activity, including in chemotherapy-resistant SCLC patient-derived xenograft models. The publication, which was co-authored by scientists from Circle Pharma and the Dana-Farber Cancer Institute, Harvard Medical School, the University of Texas Southwestern Medical Center, and the University of Oxford, can be accessed here (doi: 10.1038/s41586-025-09433-w). 'We are excited to have the novel biology and compelling anti-cancer effects of the cyclin A/B RxL inhibitors developed at Circle recognized within the broader scientific community through this publication in Nature,' said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. 'This work underscores the capabilities of our MXMO™ platform to generate oral, cell-permeable macrocycle therapies, such as CID-078, including for historically undruggable targets such as cyclins. With our first-in-human Phase 1 study of CID-078 well underway, we are eager to see the innovative research outlined in this publication translate into new, high-impact therapeutic options for people living with cancer.' 'These findings build upon previous work and reveal additional gain-of-function mechanisms through which cyclin A/B RxL inhibition triggers apoptosis in cancer cells, further supporting this approach for E2F-driven cancers, such as cancers with RB1 alterations, which includes nearly all SCLCs, up to half of triple-negative breast cancers, and subsets of other solid tumors,' said Matthew G. Oser, M.D., Ph.D., senior author of the publication and associate professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School. 'Circle Pharma's cell-permeable, oral macrocycles are designed to overcome the limitations of other therapeutic modalities and are ideally positioned to access cyclins and other historically undruggable targets, offering exciting potential for patients with cancer.' About CID-078, Circle Pharma's Oral Cyclin A/B RxL Inhibitor Program CID-078 is an orally bioavailable macrocycle with dual activity blocking protein-protein interactions between both cyclins A and B and key substrates that bind to them via conserved RxL motifs. CID-078 selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation, including alterations in the tumor suppressor RB1. In pre-clinical studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and MYT1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center Phase 1 clinical trial (NCT06577987) is currently enrolling patients with advanced solid tumors harboring RB1 alterations. About Circle Pharma Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company's lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at and follow us on LinkedIn and X.
Medscape
2 hours ago
- Medscape
Behavioral Activation Therapy Cuts Perinatal Suicide Risk
TOPLINE: In a study of 1117 perinatal adults receiving behavioral activation therapy, the odds of endorsing suicide ideation decreased by 25% with each treatment session and by 80% at 3 months post-randomization, with specialist and nonspecialist providers showing equal effectiveness. METHODOLOGY: A multisite, noninferiority, four-arm randomized clinical trial called the Scaling Up Maternal Mental healthcare by Increasing access to Treatment (SUMMIT) compared clinicians (nonspecialist vs specialist) and modalities (telemedicine vs in-person) in delivering behavioral activation therapy. Research was conducted at university-affiliated networks in Chicago, Illinois; Chapel Hill, North Carolina; and Toronto, Ontario, Canada. Participants included pregnant (≤ 36 weeks) and postpartum (4-30 weeks) adults with depressive symptoms (Edinburgh Postnatal Depression Scale score ≥ 10). A total of 1117 participants who completed at least one treatment session and provided ≥ 1 week of Edinburgh Postnatal Depression Scale data were included in the analysis. Treatment consisted of a manualized 6- to 8-session perinatal behavioral activation intervention delivered weekly. TAKEAWAY: Among 1230 enrolled pregnant and postpartum adults, 1117 completed at least one treatment session, with 264 (23.6%) endorsing suicide ideation during treatment. The odds of endorsing suicide ideation decreased by 25% with each additional treatment session (odds ratio [OR], 0.75; 95% CI, 0.58-0.96; P = .03). At 3 months post-randomization, the odds of endorsing suicide ideation decreased by 80% compared with any time during treatment (OR, 0.20; 95% CI, 0.14-0.27; P < .001). No significant differences were found in the odds of endorsing suicide ideation between clinician types (nonspecialist vs specialist) or delivery modalities (telemedicine vs in person). IN PRACTICE: 'Behavioral activation is a first-line recommended treatment for perinatal depression and may reduce postpartum suicide risk by increasing values-consistent living and awareness of ineffective behaviors,' wrote the authors of the study. SOURCE: The study was led by Parisa Kaliush, PhD, Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, and Daisy Singla, PhD, Centre for Addiction and Mental Health in Toronto. It was published online in JAMA Psychiatry. LIMITATIONS: High suicide risk prompted exclusion from SUMMIT trial, and the final sample was highly educated, suggesting some limitations in generalizability. However, the prevalence of suicide ideation at baseline (15.0%) was higher than previously cited rates. DISCLOSURES: This study was funded by the Patient-Centered Outcomes Research Institute. Bradley Gaynes, PhD, disclosed receiving compensation for authorship/review of UpToDate chapters on depression. Samantha Meltzer-Brody, MD, MPH, reported receiving research funding to the University of North Carolina for clinical trials sponsored by Sage Therapeutics, Electromedical Products International, and Sirtsei Pharmaceuticals, serving as a clinical advisor and professional corporation owner for Modern Health, and serving as a scientific advisor to EmbarkNeuro and Seaport Therapeutics. Simone Vigod, MD, disclosed receiving royalties from UpToDate for authorship of materials on depression and pregnancy. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
